Replies to post #59 on Dendreon Corp fka DNDNQ

[walldiver]

I don't know his personal details, except that he has held executive-level positions in more than one biopharma company on the science side of things (CSO, CMO, etc.), not the promotional side of things (i.e. CEO, head of sales, etc.).

In his opinion, the biggest obstacle that the Provenge BLA faces is the FDA biostatistics wonks.

IMO, the recent arrival of Gottlieb and von Eschenbach at the top two positions in the FDA provide a counterbalance to the expected statistical nitpicking. I also know for a fact that DNDN is not one of the nine health care companies for which Gottlieb had to recuse himself from any regulatory involvement when he took the #2 position in August 2005...and I believe that his favorable opinion of Provenge expressed in his February 2005 Forbes column still holds.